Guardant Health, Inc. (NASDAQ:GH) Chief Information Officer Kumud Kalia sold shares of the company’s common stock, according to a recent SEC filing. The transaction, which took place on June 10, 2026, involved the disposal of 5,000 shares.
Kalia sold the common stock at a price of $130.406 per share, resulting in a total transaction value of approximately $652,030. The sale comes as the stock trades near its 52-week high of $134.28, following a remarkable 167% return over the past year. According to InvestingPro analysis, Guardant Health currently appears overvalued based on its Fair Value assessment. Following this sale, Kalia directly holds 44,508 shares of Guardant Health common stock. This total includes 259 shares acquired through the company’s Employee Stock Purchase Plan on May 14, 2026.
In other recent news, Guardant Health Inc. received FDA approval for its Guardant360 CDx test, a significant development for the company. This test serves as a companion diagnostic for Boehringer Ingelheim’s HERNEXEOS, targeting patients with specific mutations in lung cancer. Following this approval, Mizuho raised its price target for Guardant Health to $175, maintaining an Outperform rating. The American Cancer Society’s recommendation of the company’s Shield blood test for colorectal cancer screening also played a role in this decision.
In addition, RBC Capital initiated coverage of Guardant Health with an Outperform rating and set a price target of $185. Goldman Sachs also initiated coverage with a Buy rating, citing the FDA approval of the G360 CDx 740-gene panel as a growth driver. Wolfe Research joined in with an Outperform rating and a price target of $150, acknowledging the growth of the company’s primary oncology tests. These recent developments suggest a positive outlook from analysts for Guardant Health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for GH plus thousands of other stocks and find your next hidden gem with massive upside.